secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001104659-25-029608
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell reports FY2024 net loss $11.6M; cash only $0.4M; raises $1.64M via warrant inducement
--------------------------------------------------------------------------------

- Net loss of $11.6M ($2.31 per share) improved from $17.2M loss ($6.00 per share) in 2023.
- Cash and short-term deposits fell to $0.4M at year-end from $1.5M; company entered warrant inducement to raise ~$1.64M on April 1.
- R&D spending reduced to $4.7M from $10.7M; G&A also cut to $7.0M from $10.7M.
- Phase 3b trial of NurOwn for ALS proceeding with FDA SPA; partnership with Pluri for manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925029608/0001104659-25-029608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925029608/tm2510890d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer